- Home
- PLTR vs AZN Comparison
PLTR vs AZN Comparison
Compare PLTR & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLTR
- AZN
- Stock Information
- Founded
- PLTR 2003
- AZN 1992
- Country
- PLTR United States
- AZN United Kingdom
- Employees
- PLTR N/A
- AZN N/A
- Industry
- PLTR Retail: Computer Software & Peripheral Equipment
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- PLTR Technology
- AZN Health Care
- Exchange
- PLTR Nasdaq
- AZN Nasdaq
- Market Cap
- PLTR 283.0B
- AZN 228.9B
- IPO Year
- PLTR 2020
- AZN 1993
- Fundamental
- Price
- PLTR $131.11
- AZN $70.74
- Analyst Decision
- PLTR Hold
- AZN Strong Buy
- Analyst Count
- PLTR 19
- AZN 3
- Target Price
- PLTR $94.94
- AZN $95.00
- AVG Volume (30 Days)
- PLTR 87.3M
- AZN 3.8M
- Earning Date
- PLTR 08-04-2025
- AZN 07-24-2025
- Dividend Yield
- PLTR N/A
- AZN 2.13%
- EPS Growth
- PLTR 92.54
- AZN 22.71
- EPS
- PLTR 0.23
- AZN 4.97
- Revenue
- PLTR $3,115,024,000.00
- AZN $54,982,000,000.00
- Revenue This Year
- PLTR $38.79
- AZN $9.56
- Revenue Next Year
- PLTR $28.59
- AZN $6.09
- P/E Ratio
- PLTR $565.09
- AZN $14.38
- Revenue Growth
- PLTR 33.45
- AZN 15.48
- 52 Week Low
- PLTR $21.23
- AZN $61.24
- 52 Week High
- PLTR $148.22
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- PLTR 48.61
- AZN 48.27
- Support Level
- PLTR $128.51
- AZN $69.41
- Resistance Level
- PLTR $148.22
- AZN $72.01
- Average True Range (ATR)
- PLTR 5.76
- AZN 1.01
- MACD
- PLTR -1.69
- AZN -0.21
- Stochastic Oscillator
- PLTR 13.19
- AZN 22.28
About PLTR Palantir Technologies Inc.
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.